Ever since discovering immunotherapy as a powerful tool to help patients fight the dreadful battle against cancer, several kinds of research and developments have taken place to bolster its performance. The growth of this market worldwide, including Europe, is majorly attributed to the rising prevalence of target diseases, increasing demand for monoclonal antibodies and biosimilars, and many more. Currently, clinicians are heavily investing in immunotherapy drugs over the conventional treatments. Additionally, Monoclonal antibodies are acting as the vital weapon of the immunotherapy toolkit to recruit NK cells, a powerful replacement to the average CD8+ T cells. NK cells’ main advantage lies in their capacity to kill any malignant target cell; all it needs is the right balance of activating and inhibitory receptors with the perfect stimulation to engage. Efficiently distinguishing between transformed or virally infected cells and normal cells without the need for prior sensitization with an antigen, NK cells kill abnormal cells before specific immunity develops. An innate cytotoxic immune cell, NK cells clear out the tumor development process/area and lyse target cells following the engagement of inhibitory and activating receptors. Thereby, owing to its precision and robust performance, monoclonal antibodies coupled with NK cells are becoming the standard immunotherapy care for treating different types of cancer.
In the wake of such drastic transitions, we have compiled this issue of Pharma Tech Outlook in order to assist organisations in the task of finding accomplished solution providers to help them navigate the immunotherapy realm. In this edition, we have listed the top 10 immunotherapy solution providers 2020 in Europe to highlight the companies that can escalate the chances of your growth. Equipped with innovative technological capabilities, these enlisted solution providers are transforming the immunotherapy landscape at the cloverleaf of various disruptive technologies. Besides, the magazine comprises insights from subject-matter experts, CIOs, and CXOs in the medical sector on the latest industry trends, best practices, recent innovations, and highlights their expertise. We hope this issue of Pharma Tech Outlook helps you build the partnership you and your organisation need to foster an environment driven by robust and efficient technology.
We present to you Pharma Tech Outlook’s, “Top 10 Immunotherapy Solution Providers in Europe - 2020.”